Revenue
2019
2020
2021
2022
2023
2024
2025
SOPHiA GENETICS SA (SOPH)
Price$8.09Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $77.3M | $65.2M | $62.4M | $47.6M | $40.5M | $28.4M | $25.4M |
| Gross profit | $52.1M | $43.9M | $42.9M | $31.3M | $25.2M | $17.7M | $17.8M |
| Gross margin | 67.40% | 67.42% | 68.80% | 65.71% | 62.35% | 62.29% | 70.30% |
| Research & development | $34.2M | $34.4M | $37.0M | $35.4M | $26.6M | $18.6M | $15.0M |
| Operating expenses | $123.0M | $131.9M | $138.2M | $135.8M | $112.0M | $65.7M | $57.6M |
| Operating income | −$70.9M | −$66.6M | −$74.8M | −$87.8M | −$71.5M | −$37.4M | — |
| Operating margin | −91.76% | −102.14% | −119.97% | −184.66% | −176.73% | −131.64% | — |
| EBITDA | −$66.9M | −$62.0M | −$69.3M | −$84.0M | −$69.0M | −$35.6M | — |
| EBITDA margin | −86.62% | −95.12% | −111.14% | −176.69% | −170.51% | −125.45% | — |
| Net income | −$79.0M | −$62.5M | −$79.0M | −$87.4M | −$73.7M | −$39.3M | −$33.8M |
| Net profit margin | −102.24% | −95.89% | −126.63% | −183.87% | −182.14% | −138.52% | −133.23% |
| Basic EPSper basic share | -$1.17 | -$0.95 | -$1.22 | -$1.36 | -$1.33 | -$0.93 | — |
| Diluted EPSper diluted share | -$1.17 | -$0.95 | -$1.22 | -$1.36 | -$1.33 | -$0.93 | — |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
GENERATION INVESTMENT MANAGEMENT LLP | 6.79M |
AIGH Capital Management LLC | 3.95M |
AKRE CAPITAL MANAGEMENT LLC | 3.72M |
Camblong Jurgi | 3.6M |
ROYCE & ASSOCIATES LP | 3.38M |
PRINCIPAL FINANCIAL GROUP INC | 2.36M |
AMERIPRISE FINANCIAL INC | 2.22M |
BANQUE PICTET & CIE SA | 2.21M |
AWM Investment Company, Inc. | 1.7M |
Soleus Capital Management, L.P. | 1.57M |
SILVERCREST ASSET MANAGEMENT GROUP LLC | 1.43M |
Alta Wealth Advisors LLC | 1.41M |
KENNEDY CAPITAL MANAGEMENT LLC | 917.98K |
Archon Capital Management LLC | 691.41K |
Muken Ross | 680.49K |
ESSEX INVESTMENT MANAGEMENT CO LLC | 663.43K |
Xu Zhenyu | 622.28K |
Ossipow Vincent | 522.86K |
Ensign Peak Advisors, Inc | 444.65K |
Hodges Capital Management Inc. | 409.07K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 26, 2026Form 4 · 10b5-1 | Camblong JurgiChief Executive Officer | SellOrdinary Shares | 31.9K | $5.84 | $186.5K | 3.60M |
| Jun 26, 2026Form 4 · 10b5-1 | Camblong JurgiChief Executive Officer | SellOrdinary Shares | 18.1K | $5.73 | $103.9K | 3.60M |
| Jun 25, 2026Form 4 · 10b5-1 | Camblong JurgiChief Executive Officer | SellOrdinary Shares | 1.4K | $5.70 | $7.8K | 3.62M |
| Jun 25, 2026Form 4 · 10b5-1 | Verma AbhimanyuChief Technology Officer | SellOrdinary Shares | 6.9K | $5.51 | $38.3K | 197.5K |
| Jun 25, 2026Form 4 · 10b5-1 | Menu PhilippeChief Medical Officer | SellOrdinary Shares | 5.0K | $5.50 | $27.5K | 240.8K |